Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey (Q41709411)

7 October 2017

title

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey (English)

1 reference

7 October 2017

Joshua D Vardigan

1

1 reference

7 October 2017

Christopher E Cannon

2

1 reference

7 October 2017

Vanita Puri

3

1 reference

7 October 2017

Mandy Dancho

4

1 reference

7 October 2017

AmyJo Koser

5

1 reference

7 October 2017

Marion Wittmann

6

1 reference

7 October 2017

Scott D Kuduk

7

1 reference

7 October 2017

John J Renger

8

1 reference

7 October 2017

Jason M Uslaner

9

1 reference

7 October 2017

publication date

10 December 2014

1 reference

7 October 2017

number of pages

8

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

7 October 2017

volume

232

1 reference

7 October 2017

issue

11

1 reference

7 October 2017

page(s)

1859-1866

1 reference

Long-term course and effectiveness of combination therapy in Alzheimer disease

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Modelling dementia: effects of scopolamine on memory and attention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Human memory and the cholinergic system. A relationship to aging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Muscarinic receptor subtype pharmacology and physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Donepezil 23 mg: An empty suit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Functional analysis of muscarinic acetylcholine receptors using knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Effectiveness of antidementia drugs in delaying Alzheimer's disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

The significance of the cholinergic system in the brain during aging and in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

AD2000: donepezil in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Discontinuing donepezil or starting memantine for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3813-X

Muscarinic acetylcholine receptors: signal transduction through multiple effectors.

21 January 2018

1 reference

12 December 2020

Adrenergic, dopaminergic, and muscarinic receptor stimulation leads to PKA phosphorylation of Na-K-ATPase

1 reference

12 December 2020

The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

1 reference

12 December 2020

Successful performance by monkeys with lesions of the hippocampal formation on AB and object retrieval, two tasks that mark developmental changes in human infants

1 reference

12 December 2020

Specific involvement of Ca(2+)-calmodulin kinase II in cholinergic modulation of neuronal responsiveness

1 reference

12 December 2020

Cholinesterase inhibitors for Alzheimer's disease

1 reference

12 December 2020

Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period

1 reference

12 December 2020

Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).

1 reference

12 December 2020

Donepezil for mild cognitive impairment

1 reference

12 December 2020

Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: long-term performance and effect of transparency of the barrier.

1 reference

12 December 2020

Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs

1 reference

12 December 2020

A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Comparison with domperidone and neostigmine

1 reference

12 December 2020

Donepezil for dementia due to Alzheimer's disease

1 reference

12 December 2020

Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.

1 reference

12 December 2020

10.1007/S00213-014-3813-X

Identifiers

DOI

1 reference

Dimensions Publication ID

7 October 2017

1034301724

0 references

1 reference